Who are ADT+second-generation antiandrogens ± chemotherapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adt-second-generation-antiandrogens-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ADT+second-generation antiandrogens ± chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ADT+second-generation antiandrogens ± chemotherapy (ADT+second-generation antiandrogens ± chemotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen deprivation therapy + androgen receptor antagonist ± chemotherapy. Area: Oncology.

phase 3 Androgen deprivation therapy + androgen receptor antagonist ± chemotherapy Androgen receptor; testosterone/DHT synthesis (if abiraterone included) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ADT+second-generation antiandrogens ± chemotherapy (ADT+second-generation antiandrogens ± chemotherapy) — The First Affiliated Hospital with Nanjing Medical University. This combination suppresses androgen production and blocks androgen receptor signaling in prostate cancer cells, with optional chemotherapy to enhance cytotoxic effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ADT+second-generation antiandrogens ± chemotherapy TARGET	ADT+second-generation antiandrogens ± chemotherapy	The First Affiliated Hospital with Nanjing Medical University	phase 3	Androgen deprivation therapy + androgen receptor antagonist ± chemotherapy	Androgen receptor; testosterone/DHT synthesis (if abiraterone included)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen deprivation therapy + androgen receptor antagonist ± chemotherapy class)

The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ADT+second-generation antiandrogens ± chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/adt-second-generation-antiandrogens-chemotherapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab